Abstract
Chronic pain is frequently associated with profound alterations of neuronal systems involved in pain processing and should be considered as an actual disease state of the nervous system. It should not only be relieved, but must really be treated in suffering patients. However, some forms of chronic pain, in particular those of neuropathic origin, are most often not satisfactorily managed with currently available pharmacological agents, some of which, in addition, may be poorly tolerated by some patients. In this context, gene-based approaches may contribute to the search for a better management of chronic pain. The question then arises regarding the most appropriate level for such an intervention using gene-transfer techniques. The first experimental protocols attempted the transfer of opioid precursor genes and their overexpression mainly at the spinal level. They demonstrated the feasibility and the real interest of these approaches by showing that local overproduction of opioid peptides induced antinociceptive effects in animal models of persistent pain, of inflammatory-, neuropathic- and even cancerous origin. Although really tempting data were obtained using gene-based techniques in experimental inflammatory diseases, the possible clinical interest of these approaches in chronic pain has still to be established. Nevertheless, targeting some proinflammatory cytokines, involved not only in inflammation but also in the induction and probably the perpetuation of pain, raises the possibility to block the “development” of chronic pain rather that to “simply” relieve established ongoing pain. Future gene-based protocols will certainly target some of the recently identified molecules involved in pain transduction mechanisms, sensory nerve sensitization or pain perpetuation, and evaluate their potential interest to ideally abolish or, at least, reduce chronic pain.
Keywords: chronic pain, gene therapy, sensory neurons, spinal cord, opioid peptides, cytokines
Current Gene Therapy
Title: Gene Therapy of Chronic Pain
Volume: 3 Issue: 3
Author(s): Michel Pohl, Alice Meunier, Michel Hamon and Joao Braz
Affiliation:
Keywords: chronic pain, gene therapy, sensory neurons, spinal cord, opioid peptides, cytokines
Abstract: Chronic pain is frequently associated with profound alterations of neuronal systems involved in pain processing and should be considered as an actual disease state of the nervous system. It should not only be relieved, but must really be treated in suffering patients. However, some forms of chronic pain, in particular those of neuropathic origin, are most often not satisfactorily managed with currently available pharmacological agents, some of which, in addition, may be poorly tolerated by some patients. In this context, gene-based approaches may contribute to the search for a better management of chronic pain. The question then arises regarding the most appropriate level for such an intervention using gene-transfer techniques. The first experimental protocols attempted the transfer of opioid precursor genes and their overexpression mainly at the spinal level. They demonstrated the feasibility and the real interest of these approaches by showing that local overproduction of opioid peptides induced antinociceptive effects in animal models of persistent pain, of inflammatory-, neuropathic- and even cancerous origin. Although really tempting data were obtained using gene-based techniques in experimental inflammatory diseases, the possible clinical interest of these approaches in chronic pain has still to be established. Nevertheless, targeting some proinflammatory cytokines, involved not only in inflammation but also in the induction and probably the perpetuation of pain, raises the possibility to block the “development” of chronic pain rather that to “simply” relieve established ongoing pain. Future gene-based protocols will certainly target some of the recently identified molecules involved in pain transduction mechanisms, sensory nerve sensitization or pain perpetuation, and evaluate their potential interest to ideally abolish or, at least, reduce chronic pain.
Export Options
About this article
Cite this article as:
Pohl Michel, Meunier Alice, Hamon Michel and Braz Joao, Gene Therapy of Chronic Pain, Current Gene Therapy 2003; 3 (3) . https://dx.doi.org/10.2174/1566523034578348
DOI https://dx.doi.org/10.2174/1566523034578348 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Advances in CAR-T Cell Therapy and CRISP combination
CAR-T cell therapy is a groundbreaking immunotherapy that has transformed cancer treatment, particularly in hematological malignancies like leukemia and lymphoma. It involves engineering a patient’s own T cells to express chimeric antigen receptors (CARs) that target and destroy cancer cells. The therapy has demonstrated remarkable success, achieving durable remissions in ...read more
Melatonin Signaling in Health and Disease
Melatonin regulates a multitude of physiological functions, including circadian rhythms, acting as a scavenger of free radicals, an anti-inflammatory agent, a modulator of mitochondrial homeostasis, an antioxidant, and an enhancer of nitric oxide bioavailability. AANAT is the rate-limiting enzyme responsible for converting serotonin to NAS, which is further converted to ...read more
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers.
Programmed cell death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
The now and future of gene transfer technologies
Gene and cell therapies rely on a gene delivery system which is safe and effective. Both viral and non-viral vector systems are available with specific pros and cons. The choice of a vector system is largely dependent on the application which is a balance between target tissue/disease and safety, efficacy ...read more
Related Journals

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Anti-GD2 Antibody Therapy for GD2-Expressing Tumors
Current Cancer Drug Targets Is Hospital Autopsy Auditing Suitable for Clinical Risk Manage ment? Actualities and Perspectives of Auditing in the Autopsy Room Following Italian Law 24/2017 on Patient Safety
Current Pharmaceutical Biotechnology Re-Examining the Need for Tissue Diagnosis in Pediatric Diffuse Intrinsic Pontine Gliomas: A Review
Current Neuropharmacology New Developments in Molecular Diagnosis of Bacteremic Pneumococcal Pneumonia
Current Respiratory Medicine Reviews Autoantibodies Associated with Psychiatric Disorders
Current Neurovascular Research Impact of HIV on Regional & Cellular Organisation of the Brain
Current HIV Research Integrons and Antiseptic Resistance Genes Mediate Resistance of Acinetobacter baumannii and Pseudomonas aeruginosa Isolates from Intensive Care Unit Patients with Wound Infections
Current Molecular Medicine Antifungal Agents in Hematopoietic Stem Cell Transplantation
Current Pharmaceutical Design Fluorinated Molecules as Drugs and Imaging Agents in the CNS
Current Topics in Medicinal Chemistry The Role of Adenosine in Rheumatoid Arthritis
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Tetrahydroxystilbene Glucoside Improves Neurotrophic Factors Release in Cultured Astroglia
CNS & Neurological Disorders - Drug Targets New Insights into the Immune Response to Pneumococci
Current Respiratory Medicine Reviews Phytochemicals to Prevent Inflammation and Allergy
Recent Patents on Inflammation & Allergy Drug Discovery “Connecting the Dots” from Blood Brain Barrier Dysfunction to Neuroinflammation and Alzheimer’s Disease
Current Neurovascular Research Role of Chemokines and Their Receptors in Cancer
Current Pharmaceutical Design Current Status and Prospective Application of Stem Cell-Based Therapies for Spinal Cord Injury
Current Stem Cell Research & Therapy Neurotrophic Factors in the Pathogenesis of Neurological Disorders with Mental Retardation in Children
Current Pediatric Reviews Assessment of Atherosclerosis in Ischemic Stroke by means of Ultrasound of Extracranial/Intracranial Circulation and Serum, Urine, and Tissue Biomarkers
Current Medicinal Chemistry Aminoglycoside-Induced Ototoxicity
Current Pharmaceutical Design Immunossupressant and Organ Transplantation: Immunophilins Targeting Agent and Alternative Therapies
Current Medicinal Chemistry